State coverage

Idaho Medicaid and GLP-1 coverage

State Medicaid · 3 documents cited

Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.

At a glance

Does not cover

Medicaid, for obesity: No anti-obesity drug appears on the current statewide list; the diabetes GLP-1s are covered for diabetes only.

Appeal deadline: 28 calendar days from the date on the notice source

Primary source: Idaho Department of Health and Welfare, Idaho Medicaid Preferred Drug List with Prior Authorization Criteria

Date read: September 2026

American GLP, Publisher · Who writes this site

Idaho runs a single, statewide fee-for-service pharmacy benefit through Prime Therapeutics — as of this read, the state was still surveying members and providers about a future shift to managed care, not operating one yet — so its Preferred Drug List is the one document that answers this question for essentially every Idaho Medicaid member, not one of several competing plan formularies.

That list, current as of September 1, 2026 for a July 1, 2026 effective date, has a GLP-1 class with exactly the drugs you'd expect for diabetes — Ozempic, Trulicity and Victoza preferred; Mounjaro, Byetta, Bydureon, Xultophy and Soliqua non-preferred, each gated behind a type 2 diabetes diagnosis code — and nothing else. Wegovy, Zepbound and Saxenda do not appear anywhere in the 42-page combined drug-list-and-criteria document, under any name, tier or footnote.

That absence is not backed by a named regulatory exclusion the way Alaska's is. Idaho's own excluded-drug-products rule lists fertility agents, cosmetic and hair-growth agents, cough-and-cold symptom relievers, and erectile-dysfunction agents by name — weight-loss or anti-obesity agents are not on that list. The state's coverage decision here appears to live entirely in what its Pharmacy and Therapeutics Committee has and hasn't added to the drug list, not in a written exclusion; the list's own front matter notes that any newly launched drug starts non-preferred "until reviewed by the Department of Health and Welfare Pharmacy and Therapeutics committee," though that alone would not explain a drug approved as far back as 2021 (Wegovy) never appearing at all.

We also checked the state's 196-page Medical Services provider handbook, which covers bariatric surgery for weight loss in detail but does not mention any GLP-1 drug by name, and the Department's Pharmacy and Therapeutics Committee page, which carries no GLP-1 or obesity-specific content as of this read.

What we could verify for Idaho

The state's current GLP-1 class covers diabetes only, by diagnosis code, and lists no anti-obesity brand: "HYPOGLYCEMICS, INCRETIN MIMETICS... Glucagon-like Peptide-1 (GLP-1) Receptor Agonists... Preferred Agents: OZEMPIC pen (semaglutide), TRULICITY (dulaglutide), VICTOZA (liraglutide)... Non-Preferred Agents: BYDUREON BCISE (exenatide), BYETTA (exenatide), exenatide pen, liraglutide, MOUNJARO (tirzepatide), OZEMPIC tablet (semaglutide)... SOLIQUA... XULTOPHY... Criteria for Preferred Agent: ICD-10 diagnosis of type 2 diabetes mellitus in member's record or submitted with pharmacy claim."

Idaho Department of Health and Welfare, Idaho Medicaid Preferred Drug List with Prior Authorization Criteria, effective July 2026 · source

The state's general excluded-drug regulation names four specific categories, and weight loss is not one of them: "Idaho Medicaid excludes from coverage the following drugs or classes of drugs... a. Agents, when used to promote fertility. b. Agents, when used for cosmetic purposes or hair growth. c. Agents, when used for the symptomatic relief of cough and colds... e. Agents, when used for the treatment of sexual or erectile dysfunction, unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration."

Idaho Administrative Code, IDAPA 16.03.09.662 (Prescription Drugs: Coverage and Limitations), effective March 2022 · source

The same drug list explains why a newly launched drug can be missing from a class without a formal exclusion: "Agents that are new to the market will be non-preferred until reviewed by the Department of Health and Welfare Pharmacy and Therapeutics committee." The list gives no indication such a review has happened for any anti-obesity GLP-1.

Idaho Department of Health and Welfare, Idaho Medicaid Preferred Drug List with Prior Authorization Criteria, effective July 2026 · source

Idaho gives Medicaid members 28 days to appeal a coverage decision: "If the department makes a decision about the Medicaid services and benefits you receive... and you disagree with that decision, or you believe the amount of benefit you receive is incorrect, you have the right to file an appeal. You have 28 days from the date on your notice about the decision to file an appeal about Medicaid services."

Idaho Department of Health and Welfare, Appeals and Fair Hearings · source

Idaho is one of 6 states whose Medicaid gives the same answer: weight loss excluded, and no other route named. Idaho Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Idaho with the rest in the coverage matrix.

Regional insurers that sell plans in Idaho and have their own page here, quoted from their own policy documents: Regence. The national insurers are on the insurance index.

If you work for the State of Idaho

State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State of Idaho employee health plan (Office of Group Insurance). Its pharmacy benefit runs through Regence BlueShield of Idaho (drug benefit is part of the medical plan).

Weight loss drugs not covered since Nov. 2025

Idaho stopped covering all weight loss drugs, including Wegovy, Zepbound and Saxenda, on November 1, 2025. GLP-1s prescribed for diabetes are still covered, and you can join Omada's weight program at no extra cost.

"Effective November 1, 2025, coverage for all medications prescribed for weight loss will be discontinued."